Vaccination against influenza serves as a critical measure for disease prevention, significantly mitigating the socio-economic impacts of influenza epidemics. This study conducted a comprehensive analysis of global influenza vaccine-related patents retrieved from the PatSnap global patent database, examining multiple dimensions including patent application trends, geographical distribution, patent classifications, and rankings of key applicants. Furthermore, it investigated the technological focal points in existing patents and analyzed the patent portfolios of major applicants, with the aim of providing strategic recommendations for domestic influenza vaccine R&D and patent deployment. Statistical analysis revealed a phased growth pattern in influenza vaccine patent applications, with China and the United States dominating both technology origination and target markets. While multinational corporations like GlaxoSmithKline lead in industrial applications, China's applicants primarily consist of universities and research institutions, demonstrating lower industrialization rates. The study proposes three strategic initiatives: enhancing international collaboration for universal vaccine development, strengthening quality supervision systems, and prioritizing intellectual property protection for next-generation vaccine technologies such as nucleic acid vaccines. These recommendations aim to bolster the global competitiveness of China's influenza vaccine industry.